RNS & Investor News

Supply agreement for LPLDL® in the Baltic States

07 February 2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its 100% owned subsidiary, ProBiotix Health Ltd, has entered into a three-year supply agreement with Biolat JSC ("Biolat") covering the supply of its cholesterol and blood pressure reducing LPLDL® strain in Estonia, Latvia and Lithuania.

The agreement grants Biolat a non-exclusive license to package and commercialise own label capsular food products featuring OptiBiotix's proprietary strain Lactobacillus plantarum LPLDL®, with a view to maximising the financial return for both parties. It also provides mutual commercial commitment with ongoing revenue and reflects the growing confidence in the science behind LPLDL® as a functional ingredient, as well as the growing demand for science based food supplement products in the Eastern European market.

Biolat has over 25 years' experience in the manufacturing and distribution of high quality and scientifically validated innovative natural products. Based in Latvia, it is one of the leading players in pharmacy distribution of these products in the Baltics region.

According to Eurostat (2018), the Baltic Member States record the highest death rates from diseases of the circulatory system in the entire EU, with cardiovascular-related fatalities accounting for 50-60% of all deaths. This is also one of the regions where females have the greatest cardiovascular risk - the proportions of women dying from this cause are up to 20% higher than those for men.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this supply agreement with Biolat, which further reinforces the presence of the LPLDL® in a wide range of products in Eastern Europe, where heart disease is a major public health issue. We decided to partner up with Biolat for their experience in the field of natural products manufacturing and distribution and their knowledge of this geographic area. They also have an outstanding track record of successful product launches leading to long-term revenue generation and growth."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
   
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner
Tel: 020 7213 0880
   
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Tel: 020 7220 0500
   
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.